Prenatal antibiotics exposure and the risk of autism spectrum disorders: A population-based cohort study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 15 01 2019
accepted: 25 06 2019
entrez: 30 8 2019
pubmed: 30 8 2019
medline: 10 3 2020
Statut: epublish

Résumé

Prenatal antibiotic exposure induces changes in infants' gut microbiota composition and is suggested as a possible contributor in the development of autism spectrum disorders (ASD). In this study, we examined the association between prenatal antibiotic exposure and the risk of ASD. This was a population-based cohort study utilizing the Manitoba Population Research Data Repository. The cohort included 214 834 children born in Manitoba, Canada between April 1, 1998 and March 31, 2016. Exposure was defined as having filled one or more antibiotic prescription during pregnancy. The outcome was autism spectrum disorder diagnosis. Multivariable Cox proportional hazards regression was used to estimate the risk of developing ASD in the overall cohort and in a sibling cohort. Of all subjects, 80 750 (37.6%) were exposed to antibiotics prenatally. During follow-up, 2965 children received an ASD diagnosis. Compared to children who were not exposed to antibiotics prenatally, those who were exposed had a higher risk of ASD: (adjusted HR 1.10 [95% CI 1.01, 1.19]). The association was observed in those exposed to antibiotics in the second or third trimester (HR 1.11 [95% CI 1.01, 1.23] and 1.17 [95% CI 1.06, 1.30], respectively). In the siblings' cohort, ASD risk estimate remained unchanged (adjusted HR 1.08 [95% CI 0.90, 1.30], although it was not statistically significant. Prenatal antibiotic exposure is associated with a small increase in the risk of ASD. Given the potential of residual confounding beyond what it was controlled through our study design and because of possible confounding by indication, such a small risk increase in the population is not expected to be clinically significant.

Sections du résumé

BACKGROUND
Prenatal antibiotic exposure induces changes in infants' gut microbiota composition and is suggested as a possible contributor in the development of autism spectrum disorders (ASD). In this study, we examined the association between prenatal antibiotic exposure and the risk of ASD.
METHODS
This was a population-based cohort study utilizing the Manitoba Population Research Data Repository. The cohort included 214 834 children born in Manitoba, Canada between April 1, 1998 and March 31, 2016. Exposure was defined as having filled one or more antibiotic prescription during pregnancy. The outcome was autism spectrum disorder diagnosis. Multivariable Cox proportional hazards regression was used to estimate the risk of developing ASD in the overall cohort and in a sibling cohort.
RESULTS
Of all subjects, 80 750 (37.6%) were exposed to antibiotics prenatally. During follow-up, 2965 children received an ASD diagnosis. Compared to children who were not exposed to antibiotics prenatally, those who were exposed had a higher risk of ASD: (adjusted HR 1.10 [95% CI 1.01, 1.19]). The association was observed in those exposed to antibiotics in the second or third trimester (HR 1.11 [95% CI 1.01, 1.23] and 1.17 [95% CI 1.06, 1.30], respectively). In the siblings' cohort, ASD risk estimate remained unchanged (adjusted HR 1.08 [95% CI 0.90, 1.30], although it was not statistically significant.
CONCLUSIONS
Prenatal antibiotic exposure is associated with a small increase in the risk of ASD. Given the potential of residual confounding beyond what it was controlled through our study design and because of possible confounding by indication, such a small risk increase in the population is not expected to be clinically significant.

Identifiants

pubmed: 31465485
doi: 10.1371/journal.pone.0221921
pii: PONE-D-19-01346
pmc: PMC6715235
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0221921

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Appl Environ Microbiol. 2004 Nov;70(11):6459-65
pubmed: 15528506
J Med Microbiol. 2005 Oct;54(Pt 10):987-91
pubmed: 16157555
Curr Microbiol. 2005 Oct;51(4):270-4
pubmed: 16187156
Pharmacoepidemiol Drug Saf. 2006 May;15(5):327-37
pubmed: 16557603
Chronic Dis Can. 2009;29(3):102-7
pubmed: 19527568
Br J Psychiatry. 2009 Jul;195(1):7-14
pubmed: 19567888
J Antimicrob Chemother. 2010 Oct;65(10):2238-46
pubmed: 20716554
Arch Gen Psychiatry. 2011 Nov;68(11):1095-102
pubmed: 21727249
Pediatrics. 2011 Aug;128(2):344-55
pubmed: 21746727
Trends Cogn Sci. 2011 Sep;15(9):409-16
pubmed: 21855394
Pediatrics. 2012 Dec;130(6):e1447-54
pubmed: 23147969
BMJ Open. 2013 Oct 16;3(10):e003219
pubmed: 24131525
J Autism Dev Disord. 2015 Dec;45(12):4015-25
pubmed: 24366406
Nutr Neurosci. 2015 May;18(4):145-61
pubmed: 24621061
BJOG. 2014 Jul;121(8):988-96
pubmed: 24754708
J Matern Fetal Neonatal Med. 2015 Jan;28(2):210-5
pubmed: 24766037
Sci Transl Med. 2014 May 21;6(237):237ra65
pubmed: 24848255
Trends Mol Med. 2014 Sep;20(9):509-18
pubmed: 24956966
Scand J Immunol. 2014 Oct;80(4):250-60
pubmed: 24965690
Psychiatry Res. 2014 Dec 15;220(1-2):410-7
pubmed: 25085792
Paediatr Perinat Epidemiol. 2015 Jul;29(4):307-16
pubmed: 25989831
Clin Ther. 2015 May 1;37(5):984-95
pubmed: 26046241
Pediatrics. 2015 Oct;136 Suppl 1:S41-59
pubmed: 26430169
JAMA Pediatr. 2016 Feb;170(2):117-24
pubmed: 26660917
MMWR Surveill Summ. 2016 Apr 01;65(3):1-23
pubmed: 27031587
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Nat Microbiol. 2018 Feb;3(2):234-242
pubmed: 29180726
Can J Public Health. 2018 Jan 22;108(5-6):e530-e538
pubmed: 29356660

Auteurs

Amani F Hamad (AF)

College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Silvia Alessi-Severini (S)

College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Manitoba Centre for Health Policy, Max Ray College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Salaheddin M Mahmud (SM)

College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Department of Community Health Sciences, Max Ray College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Vaccine and Drug Evaluation Centre, University of Manitoba, Winnipeg, Canada.

Marni Brownell (M)

Manitoba Centre for Health Policy, Max Ray College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Department of Community Health Sciences, Max Ray College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

I Fan Kuo (IF)

College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH